Caron Michel, Joubert-Caron Raymonde
Protein Biochemistry and Proteomics Laboratory, Université Paris 13, UFR SMBH, 74, Rue Marcel Cachin, 93017 Bobigny Cedex, France.
Expert Rev Proteomics. 2005 Aug;2(4):567-76. doi: 10.1586/14789450.2.4.567.
Basic science research in hematology has been determining the functions of gene products using classical approaches that typically involve studying one or a few genes at a time. Proteomics, defined as the study of protein properties on a large scale, provides tools to globally analyze malignant hematologic cells. A major challenge in cancer therapy is the identification of drugs that kill tumor cells while preserving normal cells. Differential display via proteomics enables analysis of direct as well as side-effects of drugs at a molecular level. Proteomics also allows a better understanding of cell signaling pathways involved during apoptosis in hematologic cells. Storing the information in a 2D electrophoresis database enhances the efficiency of proteome research on malignant cells. Finally, the work needed to be carried out on proteomic analysis prior to routine clinical adoption is discussed, and the necessity for multi-institutional collaborations is emphasized.
血液学基础科学研究一直使用传统方法来确定基因产物的功能，这些方法通常一次只研究一个或几个基因。蛋白质组学被定义为大规模研究蛋白质特性，它提供了在全球范围内分析恶性血液学细胞的工具。癌症治疗中的一个主要挑战是识别能够杀死肿瘤细胞同时保留正常细胞的药物。通过蛋白质组学进行差异显示能够在分子水平上分析药物的直接作用和副作用。蛋白质组学还能更好地理解血液学细胞凋亡过程中涉及的细胞信号通路。将信息存储在二维电泳数据库中可提高对恶性细胞蛋白质组研究的效率。最后，讨论了在常规临床应用之前进行蛋白质组分析所需开展的工作，并强调了多机构合作的必要性。
